Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹250.80 Cr |
| Fresh Issue | ₹250.80 Cr |
| Face Value | ₹2 Per Equity Share |
| Price Band | ₹108.00-114.00 per share |
| BSE Code | 544666 |
| NSE Code | GKSL |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Nirbhay Capital Services Pvt.Ltd. |
| Allotment Status |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 128 shares and in multiples thereof
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) specializes in providing multispeciality healthcare services, including secondary and tertiary care, across multiple locations in Gujarat, India.
The company operates seven multispeciality hospitals and four pharmacies with a total bed capacity of 490 beds, an approved capacity of 455 beds, and an operational capacity of 340 beds.
The company's hospitals include Gujarat Kidney and Superspeciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), and Ashwini Medical Centre (Anand). The company also operates Ashwini Medical Store (Anand).
Services:
Gujarat Superspeciality Hospital provides medical care in areas such as internal medicine, general surgery, minimally invasive procedures, orthopaedics and trauma treatment, joint replacement surgery, obstetrics and gynaecology, respiratory failure, non-interventional cardiology, diabetology, and anaesthesiology.
As of June 30, 2025, the company had 89 Doctors, 332 nurses and 338 other staff.
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Proposed acquisition of Parekhs Hospital at Ahmedabad. | 77.00 |
| 2 | Part-payment of purchase consideration for the already acquired “Ashwini Medical Centre”. | 12.40 |
| 3 | Funding of capital expenditure requirements of the Company towards setting up of a new hospital in Vadodara. | 30.10 |
| 4 | Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital in Vadodara location. | 6.83 |
| 5 | Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by the Company | 1.20 |
| 6 | Funding inorganic growth through unidentified acquisitions and General Corporate Purposes. | 87.44 |
| 7 | Acquisition of additional shareholding in the subsidiary namely “Harmony Medicare Private Limited” at Bharuch | 10.78 |
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 61.59 | 55.34 | 20.53 | 3.87 |
| Total Income | 15.27 | 40.40 | 5.48 | 0.00 |
| Profit After Tax | 5.40 | 9.50 | 1.71 | -0.01 |
| EBITDA | 8.63 | 16.55 | 1.95 | -0.01 |
| NET Worth | 30.56 | 25.71 | 10.80 | 0.37 |
| Reserves and Surplus | 19.42 | 14.57 | 10.60 | 0.17 |
| Total Borrowing | 4.03 | 3.88 | 1.94 | |
| Amount in ₹ Crore | ||||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 36.61% |
| ROCE | 37.65% |
| Debt / Equity | 0.15% |
| RoNW | 36.61% |
| PAT Margin | 23.61% |
| EBITDA Margin | 41.12% |
| Price to Book Value | 22.62 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 1.85 | 2.74 |
| P/E (x) | 61.62 | 41.59 |
| Promoter Holding | 99.1% | 71.45% |
| Market Cap | ₹898.81 Cr. | |
